Test Your Biomarkers’ Post

How might my biomarkers be tested? Biomarkers can be tested for in biopsies or in blood. It is important to test for biomarkers as soon as treatment is being considered. Every stomach cancer is unique, and testing early for your cancer’s specific biomarkers ensures that you and your healthcare team can identify the very best personalized treatment options – now and in the future.

Biomarker testing is crucial in lung cancer care, yet our recent survey reveals some critical gaps: ▪️Nearly 1/4 of EGFR+ UK patients are unaware of their mutation type. ▪️Over 1/2 are not offered rebiopsy upon progression. Better communication is essential for patients to know their biomarkers, self-advocate, and be proactive in their treatment journey. 📊 All data from EGFR+ UK 2024 Members’ Survey. See the full report https://lnkd.in/eiN8UiKi #LungCancerAwareness #BiomarkerTesting #PatientAdvocacy #EGFRPositiveUK

Eligibility criteria for CAB test is based on the parameters such as the stage of Cancer, Hormone positivity - Estrogen Receptor [ER+] or Progesterone Receptor [PR+] and has HER2 receptor-negative. The removal of the tumor helps reveal these factors and the biomarkers determine the eligibility criteria. For any further information on Can Assist Breast Test, call us on +91 84690 98432. Our team will guide them through the process and furnish details about the CanAssist Breast Test. #CanAssistBreast #breastcancerawareness #breastcancersupport #BreastCancerTest #cancerawareness #CancerTreatment #cancersupport #FightAgainstBreastCancer #healthcare #DiagnosticTesting #cancerdiagnosis #cancerdetection

Get ahead of the curve in lung cancer treatment by utilizing biomarker testing. Watch this video clip where Dr. Eric Flenaugh discusses this method during a workshop in Augusta. Biomarker testing provides the most accurate treatment for the disease and can significantly improve patient outcomes. Amgen #LungCancer #BiomarkerTesting #PrecisionMedicine

We have just published a new prospective non-interventional study showing real-world clinic utility of ThyroidPrint. Up to 67% of patients undergoing molecular testing for indeterminate thyroid cytology were called benign (Benign Call Rate). With a minimum of 18 months of followup, 99% of these patients remained under surveillance. Furthermore, the post-test cancer probability in patients undergoing ThyroidPrint testing was 71% when compared to the 32% of patient that did not undergo testing. This data provides new evidence of the benefit of molecular testing in well selected patients with indeterminate thyroid cytology. https://lnkd.in/eX39eufg #ThyroidPrint #indeterminatethyroidcytology #KeepYourThyroid #Thyroidcancer

#Healthcareproviders: Biomarker testing is a crucial element in the diagnosis process for patients living with #metastaticbreastcancer. By exploring the distinct characteristics of the cancer cells, biomarkers may reveal a targeted treatment that is specific to your patient's #biomarker. Learn more about this step on the #NoOneMissed website: https://lnkd.in/e2J__vw3

👏 We are excited to announce that AmoyDx® Pan Lung Cancer PCR Panel has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) as a companion diagnostic for TABRECTA™ (capmatinib) – designed for patients with unresectable, advanced, or recurrent non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations. 🎆 The AmoyDx PLC Panel detects alterations across 11 critical driver genes and identifies actionable mutations in seven of these genes which are directly linked to twelve targeted NSCLC therapies. This approval marks a significant advancement in precision cancer treatment with the potential to significantly enhance patient outcomes. Read the full press release here 👉 : https://lnkd.in/g9BRamEn #PrecisionMedicine #Oncology #NSCLC #LungCancer #Cancer

Commonly Used Anesthetic is Surprisingly Effective at Killing Cancer Cells: Lidocaine functions as a local anesthetic by blocking signals at nerve endings in the skin, making it a go-to choice for pain relief during medical procedures. However, its newfound role in cancer treatment has left many baffled. At the heart of this discovery lies the activation of a taste receptor known as T2R14 by lidocaine. This receptor, responsible for detecting bitterness, was found to be present in high concentrations within various cancer cells, especially those residing in the oral cavity and throat. #cancer #oncology #prostatecancer #skincanc #innovation #biotech #celltherapy #genetherapy #immunotherapy #drugdiscovery #drugdelivery #medicalsciences #pharmaceutics #medicine #research #health

Could a simple blood test change the course of colon cancer treatment? A promising new biomarker is showing incredible potential to revolutionize how we treat colon cancer. Here's why this is a major step forward: ⦿ Personalized medicine: By identifying a unique biomarker, doctors can tailor treatments to each patient's specific needs, increasing the chances of success. ⦿ Early detection: This biomarker has the potential to detect colon cancer earlier, when it's most treatable. ⦿ More effective treatment: By matching patients to the right therapy, we can reduce side effects and improve overall outcomes. What do you think this means for the future of cancer care? Let's spark a conversation! #coloncancer #biomarker #precisionmedicine #cancerresearch #healthcare

𝐖𝐡𝐲 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 𝐦𝐚𝐭𝐭𝐞𝐫? We want to share with you an informative video from the Cholangiocarcinoma Foundation elucidating the importance of biomarkers. This resource serves as an invaluable tool for individuals seeking deeper insights into the subject matter. https://lnkd.in/eJqrQSkh #liquidbiopsies #biomarkers #cancer